Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Larry M Karnitz

Showing results (31-40 of 53) with videos related to

Pageof 6
Sort By:
The Journal of Biological Chemistry|April 15, 2008
Mitotic phosphorylation stimulates DNA relaxation activity of human topoisomerase IJennifer S Hackbarth, Marina Galvez-Peralta, Nga T Dai, et al.
The Journal of Biological Chemistry|February 28, 2004
Rad9 protects cells from topoisomerase poison-induced cell deathDavid Loegering, Sonnet J H Arlander, Jennifer Hackbarth, et al.
Nature Communications|October 13, 2019
ZC3H18 specifically binds and activates the BRCA1 promoter to facilitate homologous recombination in ovarian cancerArun Kanakkanthara, Catherine J Huntoon, Xiaonan Hou, et al.
Nature Metabolism|July 6, 2021
Enzymatic activation of pyruvate kinase increases cytosolic oxaloacetate to inhibit the Warburg effectElizabeth K Wiese, Sadae Hitosugi, Sharon T Loa, et al.
Molecular Pharmacology|May 30, 2008
Overcoming S-phase checkpoint-mediated resistance: sequence-dependent synergy of gemcitabine and 7-ethyl-10-hydroxycamptothecin (SN-38) in human carcinoma cell linesMarina Gálvez-Peralta, Nga T Dai, David A Loegering, et al.
BMC Bioinformatics|August 5, 2022
DAGBagM: learning directed acyclic graphs of mixed variables with an application to identify protein biomarkers for treatment response in ovarian cancerShrabanti Chowdhury, Ru Wang, Qing Yu, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 8, 2012
Effects of selective checkpoint kinase 1 inhibition on cytarabine cytotoxicity in acute myelogenous leukemia cells in vitroErin L Schenk, Brian D Koh, Karen S Flatten, et al.
Gynecologic Oncology|November 4, 2011
A phase II study of gemcitabine in combination with tanespimycin in advanced epithelial ovarian and primary peritoneal carcinomaAndrea E Wahner Hendrickson, Ann L Oberg, Gretchen Glaser, et al.
Scientific Reports|March 7, 2019
Effect of CHK1 Inhibition on CPX-351 Cytotoxicity in vitro and ex vivoNicole D Vincelette, Husheng Ding, Amelia M Huehls, et al.
Cell Cycle (Georgetown, Tex.)|January 25, 2007
Pharmacological abrogation of S-phase checkpoint enhances the anti-tumor activity of gemcitabine in vivoDavid J Matthews, F Michael Yakes, Jason Chen, et al.
Pageof 6

Showing results (31-40 of 53) with videos related to

Sort By:
Pageof 6
The Journal of Biological Chemistry|April 15, 2008
Mitotic phosphorylation stimulates DNA relaxation activity of human topoisomerase IJennifer S Hackbarth, Marina Galvez-Peralta, Nga T Dai, et al.
The Journal of Biological Chemistry|February 28, 2004
Rad9 protects cells from topoisomerase poison-induced cell deathDavid Loegering, Sonnet J H Arlander, Jennifer Hackbarth, et al.
Nature Communications|October 13, 2019
ZC3H18 specifically binds and activates the BRCA1 promoter to facilitate homologous recombination in ovarian cancerArun Kanakkanthara, Catherine J Huntoon, Xiaonan Hou, et al.
Nature Metabolism|July 6, 2021
Enzymatic activation of pyruvate kinase increases cytosolic oxaloacetate to inhibit the Warburg effectElizabeth K Wiese, Sadae Hitosugi, Sharon T Loa, et al.
Molecular Pharmacology|May 30, 2008
Overcoming S-phase checkpoint-mediated resistance: sequence-dependent synergy of gemcitabine and 7-ethyl-10-hydroxycamptothecin (SN-38) in human carcinoma cell linesMarina Gálvez-Peralta, Nga T Dai, David A Loegering, et al.
BMC Bioinformatics|August 5, 2022
DAGBagM: learning directed acyclic graphs of mixed variables with an application to identify protein biomarkers for treatment response in ovarian cancerShrabanti Chowdhury, Ru Wang, Qing Yu, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 8, 2012
Effects of selective checkpoint kinase 1 inhibition on cytarabine cytotoxicity in acute myelogenous leukemia cells in vitroErin L Schenk, Brian D Koh, Karen S Flatten, et al.
Gynecologic Oncology|November 4, 2011
A phase II study of gemcitabine in combination with tanespimycin in advanced epithelial ovarian and primary peritoneal carcinomaAndrea E Wahner Hendrickson, Ann L Oberg, Gretchen Glaser, et al.
Scientific Reports|March 7, 2019
Effect of CHK1 Inhibition on CPX-351 Cytotoxicity in vitro and ex vivoNicole D Vincelette, Husheng Ding, Amelia M Huehls, et al.
Cell Cycle (Georgetown, Tex.)|January 25, 2007
Pharmacological abrogation of S-phase checkpoint enhances the anti-tumor activity of gemcitabine in vivoDavid J Matthews, F Michael Yakes, Jason Chen, et al.
Pageof 6